Impact of modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen on progression-free survival

被引：0
|
作者：
Lesnock, J. [1 ]
Chu, T. [1 ]
Richard, S. [2 ]
Kubenik, M. [1 ]
Krivak, T. [1 ]
Zorn, K. [1 ]
Sukumvanich, P. [1 ]
Kelley, J. [1 ]
Edwards, R. [1 ]
机构：
[1] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Magee Womens Hosp, Wexford, PA USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [1] A modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen results in higher completion rates
    Lesnock, J.
    Richard, S. D.
    McBee, W. C.
    Zom, K. K.
    Sukumvanich, P.
    Edwards, R. P.
    Krivak, T. C.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S55 - S55
  • [2] Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin is comparable to results from GOG 172
    Barlin, J.
    Dao, F.
    Zgheib, N. Bou
    Ferguson, S.
    Sabbatini, P.
    Hensley, M.
    Konner, J.
    Tew, W.
    Aghajanian, C.
    Chi, D.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S36 - S37
  • [3] Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Barlin, Joyce N.
    Dao, Fanny
    Zgheib, Nadim Bou
    Ferguson, Sarah E.
    Sabbatini, Paul J.
    Hensley, Martee L.
    Bell-McGuinn, Katherine M.
    Konner, Jason
    Tew, William P.
    Aghajanian, Carol
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 621 - 624
  • [4] Analysis of progression-free survival, tolerability and toxicity in patients with stage III ovarian, tubal and peritoneal carcinoma treated with an outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin
    Chi, D.
    Dao, F.
    Ferguson, S.
    Sabbatini, P.
    Hensley, M.
    Konner, J.
    Tew, W.
    Bell-McGuinn, K.
    Barakat, R.
    Aghajanian, C.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S123 - S123
  • [5] Cisplatin and paclitaxel are associated with improved progression-free survival compared to cisplatin alone during interval debulking surgery with hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian cancer
    Chambers, Laura
    Horowitz, Max
    Costales, Anthony
    Yao, Meng
    Chichura, Anna
    Morton, Molly
    Gruner, Morgan
    Rose, Peter
    Michener, Chad
    Debernardo, Robert
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S58 - S59
  • [6] A new modification of the standard IV/IP paclitaxel/cisplatin chemotherapy regimen that results in higher completion rates
    Mcbee, W. C.
    Richard, S. D.
    Lesnock, J. L.
    Sukumvanich, P.
    Krivak, T. C.
    Zom, K. K.
    Kelley, J. L.
    Edwards, R. P.
    GYNECOLOGIC ONCOLOGY, 2008, 111 (02) : 373 - 374
  • [7] No Advantage for dose-dense Paclitaxel in Ovarian Cancer Progression-free Survival in Comparison to Standard Dosing is not prolonged
    Stocker, G.
    ONKOLOGE, 2016, 22 (06): : 428 - 429
  • [8] Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.
    Locke, Jennifer A.
    Pond, Gregory Russell
    Sonpavde, Guru
    Necchi, Andrea
    Giannatempo, Patrizia
    Paluri, Ravi Kumar
    Niegisch, Guenter
    Albers, Peter
    Buonerba, Carlo
    di Lorenzo, Giuseppe
    Vaishampayan, Ulka N.
    North, Scott A.
    Agarwal, Neeraj
    Hussain, Syed A.
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] Neoadjuvant Chemotherapy Treatment Modifications in Ovarian Carcinoma The Impact on Surgical Outcome and Progression-free Survival
    Salman, Lina
    Ben-Haroush, Avi
    Raban, Oded
    Yeoshoua, Effi
    Sabah, Gad
    Jakobson-Setton, Ariella
    Tsoref, Daliah
    Eitan, Ram
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (01): : 17 - 20
  • [10] The effect of age on the completion rate, complication rate and progression-free survival of patients receiving intraperitoneal chemotherapy for ovarian cancer
    Kothari, R.
    Nagel, C.
    Ivy, J.
    Salani, R.
    Argenta, P.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S47 - S48
12345